ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 610,60
0,52%
Dow Jones
38 778,10
0,49%
DAX
18 136,22
0,35%
Brent Oil
83,675
-0,27%
Bitcoin
65 299,29
-1,78%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Catalyst Pharmaceuticals Inc (CPRX)

  7. Catalyst Pharmaceuticals Inc (CPRX) Actualités

CPRX

Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CPRX
DateHeureSourceTitreSymboleSociété
11/06/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
07/06/202417h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
31/05/202422h50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CPRXCatalyst Pharmaceuticals Inc
31/05/202422h47Edgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
30/05/202422h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
30/05/202419h41GlobeNewswire Inc.Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®NASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/05/202414h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202422h16GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
01/05/202414h00GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
22/04/202414h00GlobeNewswire Inc.Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/03/202413h03GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/03/202413h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:CPRXCatalyst Pharmaceuticals Inc
13/03/202412h55GlobeNewswire Inc.Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)NASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/03/202414h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:CPRXCatalyst Pharmaceuticals Inc
29/02/202400h03GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/02/202414h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREENASDAQ:CPRXCatalyst Pharmaceuticals Inc
21/02/202415h00GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal NeurologyNASDAQ:CPRXCatalyst Pharmaceuticals Inc
14/02/202414h03GlobeNewswire Inc.Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
09/01/202422h05GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Closing of Public OfferingNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/01/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/01/202414h02GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:CPRXCatalyst Pharmaceuticals Inc
04/01/202422h49GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockNASDAQ:CPRXCatalyst Pharmaceuticals Inc
03/01/202423h18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
18/12/202312h30GlobeNewswire Inc.Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo PharmaNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/12/202314h03GlobeNewswire Inc.Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap CompaniesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
04/12/202314h03GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive PromotionsNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/11/202314h05GlobeNewswire Inc.Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/11/202322h11GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
02/11/202315h37GlobeNewswire Inc.Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®NASDAQ:CPRXCatalyst Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CPRX

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
CS
Axa
EU
GLE
Societe Generale
EU
AF
Air FranceKLM
EU
HO
Thales
EU
ACA
Credit Agricole
EU
LR
Legrand
NYSE
NKE
Nike
FTSE
UKX
FTSE 100
EU
ORA
Orange
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
EU
BNP
BNP Paribas
NASDAQ
MSFT
Microsoft
EU
AI
Air Liquide
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés